The aim of this case–control study was to evaluate the clinical and biochemical efficiency of inositol versus metformin in polycystic ovary syndrome.
Patients and methods
The 128 patients who completed the study were divided into group A, which comprised 62 patients prescribed myoinositol+D-chiroinositol at the rate of two tablets a day, and group B, which comprised 66 patients who were prescribed metformin 1500 mg every day for 3 months. Both groups were then followed up for 3 months after the end of the treatment period. All patients underwent a baseline vaginal ultrasound and evaluation of BMI and weight, antimullarian hormone (AMH), serum progesterone, and Homeostasis Model of Assessment-Insulin Resistance (HOMA-IR), and were evaluated according to clinical and biochemical outcomes.
Spontaneous menstruation and spontaneous pregnancy rates were significantly higher in group A than in group B: 46.7 and 11.2% in the inositol group compared with 13.6 and 3.0% in the metformin group. Concerning weight loss, the difference between the two groups was significant in favor of the inositol group. Significant difference was also detected by higher progesterone levels in group A, whereas AMH and HOMA-IR showed insignificant differences in both groups.
Myoinositol+D-chiroinositol yielded significantly better results in weight reduction, resumption of spontaneous ovulation, and spontaneous pregnancy compared with metformin in polycystic ovarian disease patients, whereas the effects of both drugs were comparable as regards decreasing AMH and HOMA-IR.